Gilead Sciences (GILD) said Friday that its experimental drug, trodelvy, met the primary endpoint in a phase 3 trial, showing a statistically significant and clinically meaningful improvement in progression-free survival over chemotherapy in patients with a type of breast cancer who are not candidates for immunotherapy.
The company said the drug's safety profile in the study was consistent with previous trials, with no new safety signals observed.
The drugmaker said overall survival, a key secondary endpoint, was not yet mature at the time of analysis, and further monitoring is underway.
Gilead said it is also evaluating trodelvy in multiple ongoing phase 3 studies across various tumor types, including HER2-negative breast cancer, lung, and gynecologic cancers.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。